An analysis by researchers at the Brown University School of Public Health found that most studies exclude participants who ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

The key processes of skin aging are now being understood in sufficient detail that targeted prescription therapies for ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

Mojisola Adeyeye, the director-general of the National Agency for Food and Drug Administration and Control (NAFDAC), says the ...

Neuroprosthetics research has entered a stage in which animal models and proof-of-concept studies are translated into ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

The National Agency for Food and Drug Administration and Control (NAFDAC) said it was seeking financial support to facilitate ...